Prof. Levenberg is the former Dean of the Biomedical Engineering Department at the Technion. She currently serves as the director of the Technion Center for 3D Bioprinting and The Rina & Avner Schneur Center for Diabetes Research. Prof Levenberg has received numerous prizes including the Krill Prize for excellence in scientific research, awarded by the Wolf Foundation, and was named by Scientific American as a “Research Leader” in tissue engineering, for her seminal work on vascularization of engineered tissues. She has also received the Rappaport Prize for Excellence in Biomedical Sciences and a Medal of Distinction from the Peres Center for Peace and Innovation. Prof Levenberg has authored over 150 publications, and presented her work as an invited lecturer in over 150 international conferences including as a keynote or plenary lecturer. She is founder and CSO of three start-up companies in the areas of cultured meat, spinal cord regeneration and nanoliter arrays for rapid antimicrobial susceptibility testing.
Prof Levenberg earned a PhD at the Weizmann Institute of Science, where she focused on cell adhesion dynamics and signaling, and pursued her post-doctoral research in tissue engineering at MIT, in the lab of Professor Robert Langer. Prof Levenberg spent a year as a visiting professor at the Wyss Institute for Biology Inspired Engineering at Harvard University.
Dr. Alessandra Balduini has a broad background in haematology, with specific training and expertise in the research of haematopoietic stem cell biology and clinical aspects of platelet-related disorders. Since 2007 she has led a research group in two different academic institutions: the Department of Molecular Medicine – University of Pavia (Italy) and the Department of Biomedical Engineering – Tufts University, Boston (USA). The goal was to establish a cross-sectional program that integrates biological with bioengineering approaches to the study of haematopoiesis and bone marrow environment. In 2011 she developed the groundwork for modeling human bone marrow by bioengineering a new 3D model made of porous silk that fully recreates the physiology of the living bone marrow niche environment. This system, completely redesigned in 2015 and 2017, is capable of successfully generating functional platelets ex vivo, offering new opportunities for producing blood components for clinical applications. In 2021, Balduini Lab. proved that this superior tissue system also represents a new tool for studying pathologic mechanisms of human platelet production and testing drug efficiency.
Dr. Chen is a Professor in the Nanoengineering Department at the University of California, San Diego (UCSD). He is also a faculty member of the Institute of Engineering in Medicine at UCSD. Before joiningUCSD, Dr. Chen had been a Professor and a Pearlie D. Henderson Centennial Endowed Faculty Fellow in Engineering in the Mechanical Engineering Department at the University of Texas at Austin. From 2008 to 2010, Dr. Chen served as the Program Director for the Nanomanufacturing Program in the National Science Foundation (NSF), where he directed the frontiers of nanomanufacturing research at NSF and managed 150 active grants and $18 million annual budget of the program. Dr. Chen’s primary research interests include:
Dr. Charu Chandrasekera is the founder and executive director of Canada’s first and only centre dedicated exclusively to alternatives to animal testing—the Canadian Centre for Alternatives to Animal Methods (CCAAM) and its subsidiary, the Canadian Centre for the Validation of Alternative Methods (CaCVAM) located at the University of Windsor. She obtained her Ph.D. in Biochemistry & Molecular Biology from the Faculty of Medicine at the University of Calgary, specializing in cardiovascular research. Dr. Chandrasekera is an experienced scientist, former animal researcher, science policy expert, and an animal lover. Through CCAAM/CaCVAM, Dr. Chandrasekera promotes the replacement of animals in Canadian biomedical research, education, and regulatory testing through 21st century science, innovation, and ethics.
Peyman Kelk is a university lecturer in anatomy at the Department of Integrative Medical Biology, Umeå University, Sweden. He obtained his dental degree in 2002 and completed his doctoral studies in the field of periodontology in 2009. In 2013, he became a specialist in prosthodontics and currently holds a combined position where he combines clinical work in prosthodontics with lecturing position in anatomy. His research initially focused on host-parasite interactions, but after his dissertation, he shifted his research towards stem cell biology and regenerative medicine, including 3D bioprinting for hard tissue applications. Today, he works in a larger group of researchers with the aim of making regenerative medicine and stem cell biology clinically applicable.
Sue Kimber is Professor of Stem Cells and Development at the University of Manchester, UK, Director of the MRC/EPSRC Centre for Doctoral Training in Regenerative Medicine and was Co-Director of the North West Embryonic Stem Cell Centre (NWESCC). She has over 30 years of experience in Cell and Developmental Biology and 10 years of experience in regenerative medicine and tissue engineering using human pluripotent stem cells (hPSCs) with >160 publications. Her lab have derived >30 hiPSC lines both from healthy individuals and those with disease conditions caused by mutations affecting the skeleton, kidney, nervous system and vasculature. They have generated and applied different 2D and 3D protocols for hPSC differentiation of these tissues for understanding human development and disease modelling. She has participated in two UKRI UK Regenerative Medicine Platform hubs (‘Stem Cell Niche’ and ‘Safety of Stem Cells’) and has supervised over 50 PhD students, as well as post docs and fellows. Relevant external activities include Co-Chair of 2023 meeting of European chapter of TERMIS; Founder and Co-Chair of Mercia Stem Cell Alliance to promote stem cell biology in the NW and Midland. She has recently collaborated in several tissue engineering projects using bioprinting.
CTO and Board member at Ossiform.
Has several years of experience in the development of additive manufacturing processes of medical devices and patient specific implants.
Lead responsible for Ossiform’s Production, R&D and IP.
Core achievements include the setup of Ossiform’s production conforming to ISO 13485 guidelines, with a production of +1000 implants for premarket testing, validation of the Ossiform material for intended human use, development and subsequent granting of Ossiform’s IP worldwide, as well as the adaptation of the company’s material for Point of Care Printing.
Key contributor in Ossiform’s cumulated capital raise of +$10M.
Has a M.Sc. degree in Engineering of Health Technology.
Albane is head of the Making Lab, a Science Technology Platform at the Crick, that focuses on combining approaches from engineering and biomedical research to develop innovative systems to investigate biomedical research questions from neuroscience to cell development, stem cell or cancer biology. She is particularly interested in biomaterial and biomanufacturing processes to develop new in vitro platforms with direct applications to fundamental research conducted at the Crick and the wider research community.
Ishani Malhotra, Chief Executive Officer, and founder of Carcinotech, has ten years of experience in oncology and stem cell research with degrees from the University of Edinburgh and a Certificate of Achievement from Harvard Medical School. She has experience working at Censo Biotechnologies, HCG Oncology hospitals, The Institute of Cytology and Preventative Oncology and Stempeutics, prior to launching Carcinotech. She was listed as a Director of the Year Regional finalist at the Institute of Directors Scotland 2021 awards, has won several awards at national and international platforms. She was recently recognised as one of 35 Rising Stars by Scottish Business Insider under 35, won the AccelerateHer 2022 Awards for Science and MedTech and won the Female Entrepreneur of the Year award at The Scottish SME Business Awards 2022. She has established significant international partnerships to advance Carcinotech’s vision of providing personalised drug testing platforms to help those suffering from cancer.
Dr. Kajsa Kanebratt has an MSc in Pharmacy from Uppsala University, Sweden, after which she did her PhD as an industrial PhD student at AstraZeneca in Mölndal in collaboration with Karolinska Institute in Stockholm. The focus of the thesis was predictive models for induction of cytochrome P450 enzymes, including both in vitro and in vivo studies. In 2009 she joined the In Vitro DMPK group at AstraZeneca in Mölndal as a Senior Research Scientist. Since then Dr. Kanebratt has been working on different in vitro models, most recently driving method development and implementation of 3D liver spheroids within AstraZeneca Mölndal.
Presently, Dr. Kanebratt holds a position as Associate Principal Scientist where she, in addition to laboratory work, also support drug projects from early lead generation to life cycle management with metabolism knowledge and advise.
Dr. Marco Domingos is a Senior Lecturer/Associate Professor in the Department of Mechanical, Aerospace, and Civil Engineering at the University of Manchester (UK). He graduated in Mechanical Engineering (2006) from the Polytechnic Institute of Leiria (Portugal) and holds a Ph.D. (2013) cum laude in Mechanical Engineering from the University of Girona (Spain). He was elected fellow of the Higher Education Academy (UK) in 2016 and fellow of the Institution of Mechanical Engineers (FIMechE, UK) in 2017. He holds several visiting positions at prestigious institutions including visiting Professor at the Centre for Rapid and Sustainable Product Development (CDRSP, Portugal) and at The University of Naples, Federico II (Naples, Italy). Since 2021 he is the Technology Platform Lead for Bioprinting at the Henry Royce (https://www.royce.ac.uk/technology-platforms/bioprinting-platform/), the UK national institute for advanced materials and innovation, where his group is focusing on the development of advanced biomaterials and biofabrication technologies for application in regenerative medicine. He has authored or co-authored more than 50 scientific publications, including articles in peer-reviewed international journals, books and book chapters obtaining over 3436 citations (H index: 26).